

In vitro Activity of Vancapticin against Methicillin-Resistant Staphylococcus aureus from Periprosthetic Joint Infections

Hye-Kyung Cho, MD, PhD,¹ Melissa J. Karau, MS,¹ Kerryl E. Greenwood-Quaintance, MS,¹ Karl A. Hansford, ² Matthew A. Cooper, ² Mark A.T. Blaskovich,² Robin Patel, MD^{1,3}

¹Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, MN

²Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Australia

³Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN

Fig 1. Vancapticin structure

(Blaskovich MAT, et al. Nat Commun 2018;9(1):22.)

Contact Information:
Robin Patel
Mayo Clinic, Rochester, MN
patel.robin@mayo.edu

Abstract

BACKGROUD: The vancapticins are modified vancomycin derivatives developed by adding membrane targeting motifs to the C-terminus of vancomycin. We determined the *in vitro* activity of a lead vancapticin candidate against periprosthetic joint infection-associated methicillin-resistant *S. aureus* (MRSA) in the planktonic and biofilm states, and the effect of adding 0.002% polysorbate 80 (P-80; Sigma-Aldrich) on vancapticin susceptibility testing.

METHODS: Thirty-seven clinical isolates of MRSA collected at Mayo Clinic (Rochester, Minnesota) were studied. Vancapticin minimum inhibitory concentrations (MICs) were determined using Clinical and Laboratory Standards Institutes guidelines. Minimum biofilm bactericidal concentrations (MBBCs) were determined using a pegged lid microtiter plate assay. Vancapticin MIC and MBBC values were assessed with and without P-80. Vancapticin, vancomycin, and dalbavancin biofilm time-kill assays were performed using biofilms formed by 10 MRSA isolates on Teflon coupons.

RESULTS: Vancapticin MICs with and without P-80 ranged from 0.015 to 0.12 μg/mL and 0.25 to 1 μg/mL, respectively. Vancapticin MBBCs with and without P-80 ranged from 0.25 to 4 μg/mL and 1 to 8 μg/mL, respectively. Reductions of biofilm bacterial densities on Teflon coupons after 8 and 24 hours of incubation with vancapticin, vancapticin with P-80, vancomycin, or dalbavancin with P-80 were less than 3-log10 cfu/cm² for all isolates tested.

CONCLUSION: Vancapticin has promising *in vitro* activity against planktonic MRSA and MRSA in a pegged lid biofilm assay, but was not bactericidal against biofilms on Teflon coupons. P-80 decreased vancapticin MICs and MBBCs.

Background

Periprosthetic joint infections (PJI)

- · Complication of arthroplasty associated with morbidity and mortality, most commonly caused by staphylococci
- Methicillin-resistant Staphylococcus aureus (MRSA) PJI related to increased rates of treatment failure, longer hospital stays, poorer clinical outcomes, and increased costs than PJI caused by methicillin-susceptible staphylococci

> Vancapticins

- Modified vancomycin derivatives prepared with membrane targeting motifs added to C-terminus of vancomycin
- Mechanism of action
 - ✓ Increased affinity for the target terminal *D*-Ala-*D*-Ala dipeptide of Lipid II
 - ✓ Enhanced dimerization leading to higher avidity for membrane-bound Lipid II
 - ✓ Increased membrane permeability
 - ✓ Enhanced drug concentration at the membrane surface by localizing drug

> Objectives:

- Evaluate in vitro activity of vancapticin (MCC5145) against planktonic and biofilm states of PJI associated-MRSA
- Determine effect of adding P-80 to vancapticin susceptibility testing

Methods and Results (I. MIC, MBIC, and MBBC, 37 PJI-associated MRSAs, 2000-2016)


Minimum inhibitory concentrations (MICs)


- Broth microdilution following CLSI guidelines
- ➤ Minimum biofilm inhibitory concentrations (MBICs) and minimum biofilm bactericidal concentrations (MBBCs)
- Determined using pegged lid microtiter plate assay
- Tested with and without 0.002% polysorbate 80 (TWEEN®, Sigma-Aldrich, St. Louis, MO)
- ► Table 1. Vancapticin MIC, MBIC, and MBBC of MRSA isolates (N = 37)

		MIC (μg/mL)								MIC	MIC		
		0.015	0.03	0.06	0.125	0.25	0.5	1	2	4	8	· MIC ₅₀	MIC ₉₀
	Vancapticin without P-80	0 (0)	0 (0)	0 (0)	0 (0)	18 (48.6)	17 (94.6)	2 (100)	0 (100)	0 (100)	0 (100)	0.5	0.5
n	Vancapticin with P-80	3 (8.1)	1 (10.8)	27 (83.8)	6 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0.06	0.125
"		MBIC (μg/mL)								MDIC	MDIC		
		0.015	0.03	0.06	0.125	0.25	0.5	1	2	4	8	MBIC ₅₀	MBIC ₉₀
er	Vancapticin without P-80	0 (0)	0 (0)	0 (0)	0 (0)	5 (13.5)	21 (70.3)	9 (94.6)	2 (100)	0 (100)	0 (100)	0.5	1
	Vancapticin with P-80	1 (2.7)	19 (54.1)	17 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0 (100)	0.06	0.125
١,		MBBC (μg/mL)								MDDC	MDDC		
١,		0.015	0.03	0.06	0.125	0.25	0.5	1	2	4	8	- MBBC ₅₀	MBBC ₉₀
d	Vancapticin without P-80	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.7)	19 (54.1)	9 (76.3)	8 (100)	2	8
	Vancapticin with P-80	0 (0)	0 (0)	0 (0)	0 (0)	2 (5.4)	11 (35.1)	15 (75.7)	8 (97.3)	1 (100)	0 (100)	1	2

Methods and Results

(II. Vancaptin, Vancomycin, and Dalbavancin Time-Kill Assays, 10 PJI-associated MRSAs)







- = 1X MBBC or fCmax (when MBBC >fCmax)
- Bactericidal activity: Defined as 3-log₁₀ cfu/cm² reduction at 24 h compared to biofilm bacterial density at 0 h

Table 2. MIC and MBBC values for 10 MRSA isolates

		MIC (µ	ıg/mL)		MBBC (μg/mL)					
Isolate (IDRL #)	Vancap ticin	Vancap ticin with P-80	Vanco mycin	Dalba vancin	Vancap ticin	Vancap ticin with P-80	Vanco mycin	Dalba vancin		
6169	0.25	0.015	1	0.03	1	0.5	>32	1		
7126	0.25	0.06	1	0.03	4	1	>32	1		
7680	0.25	0.06	2	0.03	2	0.25	>32	1		
8302	0.5	0.06	2	0.03	2	4	>32	1		
8454	0.5	0.06	1	0.03	2	1	>32	2		
8459	0.25	0.06	1	0.06	2	1	>32	4		
8508	0.25	0.06	1	0.03	2	0.5	>32	2		
9121	0.25	0.06	1	0.03	2	1	>32	1		
9337	0.5	0.06	1	0.25	4	1	>32	1		
11468	0.25	0.06	2	<0.008	2	2	>32	8		

Fig 2. Biofilm time-kill curves against 10 MRSA isolates (A) IDRL-6169 No treatment Vancapticin 1 µg/mL Vancapticin with P-80 0.5 µg/mL Vancapticin with P-80 1 µg/mL Dalbavancin with P-80 1 µg/mL Dalbavancin with P-80 1 µg/mL





*P < 0.05, in comparison with no treatment group at each time point

Conclusions

0 2 8 12 16 10 14

- ➤ Vancapticin (MCC5145) has promising *in vitro* activity against PJI-associated MRSA in the planktonic state and biofilms state in pegged lid assays, but was not bactericidal against biofilms on Teflon coupons.
- > The addition of P-80 decreased vancapticin MICs, MBICs and MBBCs.